JAMA Forum: For second line diabetes medications, an observational study goes where RCTs haven’t

Austin Frakt

January 14, 2015

My latest JAMA Forum post is about a recent study that found that a common diabetes drug causes harm. I discussed this study previously, but my JAMA Forum approach is more tutorial about methods. I encourage you to read it. And, I welcome your feedback, as noted at the end of the post.

@afrakt

Hidden information below

Austin Frakt

Austin Frakt, PhD, is co-Editor-in-Chief of The Incidental Economist. His day job is Associate Director of the Partnered Evidence-based Policy Resource Center at the Boston VA Healthcare System, U.S. Department of Veterans Affairs. He is also a Professor with the Department of Health Law, Policy and Management at the Boston University’s School of Public Health, a Principal Research Scientist with the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health, and Editor-in-Chief of the journal Health Services Research.

JAMA Forum: For second line diabetes medications, an observational study goes where RCTs haven’t

Hidden information below

Austin Frakt

The Incidental Economist

Editors In Chief

Managing Editor

Subscribe